Medicamen Organics Ltd
Medicamen Organics Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY25 call signalled
2 of 4 strong
The short version
Medicamen Organics targets revenues of INR 60-65 crores for FY '26. Medicamen Organics Limited targets 60% CAGR revenue growth over the next three years.
From Medicamen Organics Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Medicamen Organics targets revenues of INR 60-65 crores for FY '26.
- The company plans a 60% CAGR in revenue over the next three years.
- Expansion includes a 20% capacity increase at the Haridwar facility.
- Nepal facility expected to contribute from FY '27 onwards, with optimum potential above INR 400 crores.
- Focus on growing export markets, aiming for 75% export and 25% domestic revenue mix.
- Plans to register around 120 products in Africa over the next two years.
- Growth driven by diversification into personal care/cosmetics with INR 15 crores revenue targeted for FY '26.
2 more points from Medicamen Organics Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Medicamen Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
- Expansion of Haridwar manufacturing facility by 20% underway to enhance operational efficiency and scale production.
- Plans to construct an EU-approved manufacturing facility for better control over production, targeted commercialization starting around 15 months from now, with first-year revenue potential of INR50 crores.
- No current plans for fundraising; expansions funded through internal accruals and INR3 crores raised via convertible warrants from Promoter Group.
2 more points from Medicamen Organics Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Medicamen Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current orders in hand with the East Africa subsidiary stand at around $125,000.
- An advance payment of $50,000 has been received from the subsidiary.
- The first shipment from the East Africa operations is scheduled for this month.
- Post initial shipment, similar subsequent orders are expected.
- The company is preparing for a good influx of orders this year, supported by 20% capacity expansion at the primary facility.
2 more points from Medicamen Organics Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Medicamen Organics Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Medicamen Organics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Medicamen Organics Ltd Q4 FY25 results?
Medicamen Organics targets revenues of INR 60-65 crores for FY '26. Medicamen Organics Limited targets 60% CAGR revenue growth over the next three years.
What is Medicamen Organics Ltd share price analysis?
Medicamen Organics Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹35 Cr. Investors should review the full earnings analysis for detailed insights.
Is Medicamen Organics Ltd planning capital expenditure?
INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
Keep Medicamen Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.